Taylor G M, Ridway J C, Fergusson W D, Harris R
Br J Cancer. 1984 Apr;49(4):485-94. doi: 10.1038/bjc.1984.76.
The expression of allogenic lymphocyte-activating determinants (LAD) on 25 acute leukaemias has been compared with the expression of cell-surface antigens identified by HLA-DR allo- and xeno-antisera. The close correlation between LAD and DR known to occur on normal lymphocytes was not found in leukaemias. Twenty-two LAD+ leukaemias included 2 DR- cases, whilst 2 LAD- leukaemias were DR+. With the exception of 3 leukaemias all were strongly beta 2 microglobulin+. No correlation was found between the % DR+ cells and the level of lymphocyte stimulation. Separation of leukaemia cells on Ficoll gradients into fractions containing different proportions of DR+ cells did not correlate with LAD expression. Furthermore, antisera to DR antigens only partially blocked leukaemic LAD. The results support the notion that LAD on acute leukaemias are not necessarily associated with or identical to HLA-DR antigens, and that the lymphocyte activating capacity of HLA-DR may be modulated.
已将25例急性白血病中同种异体淋巴细胞激活决定簇(LAD)的表达与由HLA - DR同种异体和异种抗血清鉴定的细胞表面抗原的表达进行了比较。在白血病中未发现已知在正常淋巴细胞上出现的LAD与DR之间的密切相关性。22例LAD阳性白血病包括2例DR阴性病例,而2例LAD阴性白血病为DR阳性。除3例白血病外,所有病例的β2微球蛋白均呈强阳性。未发现DR阳性细胞百分比与淋巴细胞刺激水平之间存在相关性。通过Ficoll梯度将白血病细胞分离成含有不同比例DR阳性细胞的组分,这与LAD表达无关。此外,针对DR抗原的抗血清仅部分阻断白血病LAD。结果支持以下观点:急性白血病中的LAD不一定与HLA - DR抗原相关或相同,并且HLA - DR的淋巴细胞激活能力可能受到调节。